[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Universitario San Ignacio\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":165},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,69,91,113,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644010","efficacy-of-the-use-of-real-time-continuous-glucose-monitoring-on-glycemic-control-in-patients-with-type-2-diabetes-and-stage-3-and-4-chronic-kidney-disease-100644010",false,"NCT07668219","Efficacy of the Use of Real-time Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Stage 3 and 4 Chronic Kidney Disease.","4.2.1 Inclusion Criteria\n\n* Age over 18 years\n* Chronic kidney disease defined as a glomerular filtration rate (GFR) of less than 60 ml\u002Fmin\u002F1.73 m², in at least two measurements within the six months prior to inclusion.\n* Treatment with basal insulin, basal-bolus regimen, or co-formulation with or without oral antidiabetic agents, with or without a GLP-1 analogue, with stable treatment for the last 3 months.\n\n4.2.2 Exclusion Criteria\n\n* Type 1 diabetes.\n* Severe cognitive impairment or dysfunction that prevents device management.\n* Chronic kidney disease on renal replacement therapy (peritoneal dialysis or hemodialysis).\n* Patients with a history of kidney transplantation.","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"NA","* Rationale: Glucose control in patients with kidney disease is challenging, as traditional metrics can be unreliable and there is a high risk of hypoglycemia (low blood sugar). Although RT-CGM has shown benefits in other groups, its efficacy in patients with advanced kidney damage needs to be validated to improve their quality of life and prevent disease progression.\n* Main objective: To determine whether the use of RT-CGM is more effective than usual care (capillary blood glucose monitoring with a glucometer) in maintaining patients within an optimal glucose range (70-180 mg\u002FdL) over a three-month period.\n* Study population: We plan to include 30 patients over 18 years of age with type 2 diabetes and chronic kidney disease (with a glomerular filtration rate less than 60 ml\u002Fmin), who use insulin and are not on renal replacement therapy such as dialysis.\n* Methodology: The study is a randomized clinical trial consisting of two phases:\n\n  1. Selection period (15 days): Blinded monitoring is performed to obtain baseline data.\n  2. Treatment period (90 days): Patients are divided into two groups: the intervention group, which will use the CGM-RT with alarms configured for high and low levels, and the control group, which will continue with traditional fingerstick monitoring.\n* Metrics to be evaluated: In addition to time in range, researchers will analyze episodes of hypoglycemia and hyperglycemia, glycemic variability, glycated hemoglobin (HbA1c) levels, and device accuracy.\n* Ethical and logistical considerations: The study complies with international and national regulations, guaranteeing the confidentiality and autonomy of the participants. The project has a 24-month timeline and a detailed budget to cover medical personnel, monitoring sensors (Sinocare i3), and laboratory tests.",[25,26,27,28],"Type 2 Diabetes","Kidney Disease","CGM","Time in Range",[25,26,30,31],"Continuous Glucose Monitoring","Time in range","NOT_YET_RECRUITING","2026-06-19",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":19},"2026-11",{"date":40,"type":19},"2027-05-30",{"name":42,"class":43},"Hospital Universitario San Ignacio","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100644231","influence-of-the-use-of-specific-nutritional-formulas-on-time-in-range-in-patients-with-type-2-diabetes-100644231","NCT07666581","Influence of the Use of Specific Nutritional Formulas on Time in Range in Patients With Type 2 Diabetes","Influence of the Use of Specific Nutritional Formulas for Diabetes on Time in Range in Patients With Type 2 Diabetes Mellitus With Obesity by Freestyle Continuous Glucose Monitoring","Inclusion criteria:\n\n* Patients over 18 years of age.\n* Diagnosis of diabetes mellitus type 2.\n* HbA1c \\>7% to \\\u003C11%.\n* BMI \\>27 kg\u002Fmt2 \\\u003C35 kg\u002Fmt2\n* Current use of continuous glucose monitoring with adherence greater than 70%.\n* Access to technology to download data from CGM in a timely manner.\n* Ability to follow the study protocol and provide informed consent (Appendix 3).\n\nExclusion criteria:\n\n* Change in antidiabetic medication in the last 3 months.\n* Pregnancy or lactation or planning to become pregnant during the study period.\n* Acute decompensation of diabetes in the past 3 months.\n* Participation in another clinical trial.\n* Use of glucocorticoids or insulin in the past 3 months or planned use in the coming months.\n* Initiation of treatment with oral or injectable GLP-1 analogues 3 months prior to enrollment.\n* History of bariatric surgery or gastrointestinal pathology associated with malabsorption syndromes.",{"count":53,"type":19},198,[22],"Who can participate?\n\nIndividuals may be eligible to join this study if they meet the following criteria:\n\n* Are 18 years or older.\n* Have Type 2 diabetes with an A1c level higher than 7%.\n* Have a Body Mass Index (BMI) between 27 and 35 (considered overweight or Class 1 obesity).\n* Have used a continuous glucose monitor (CGM) successfully in the past.\n\nHow the study works:\n\nIf eligible individuals decide to join and sign the consent form, a computer will randomly assign them into one of two groups:\n\nThe Formula Group: Participants will replace their usual breakfast and one snack with a specific diabetes nutritional drink (Glucerna®).\n\nThe Standard Diet Group: Participants will follow a standard low-calorie meal plan without using the nutritional drink.\n\nBoth groups will aim for a specific daily calorie goal (1,200-1,500 for women; 1,500-1,800 for men) and will receive expert nutritional counseling.\n\nMonitoring and Follow-up\n\nOver the course of 3 months, close contact will be maintained to support participants:\n\nEvery 2 weeks: A nutrition expert will call participants to check on their diet and help with their glucose monitor.\n\nEvery month: Participants will meet with the study team in person to review glucose monitor data.\n\nTests: At the start and end of the study, weight, body composition, blood sugar (A1c), and cholesterol levels will be measured to see how the plans worked.",[25,57,28],"Obesity & Overweight",[25,59,60,28],"Obesity","Continuos Glucose Monitoring","2026-06-18",{"date":63,"type":36},"2026-06-24",{"date":65,"type":19},"2026-08",{"date":67,"type":19},"2028-12",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":44},"100616693","real-time-continuous-glucose-monitoring-compared-with-intermittent-continuous-glucose-monitoring-in-people-with-type-2-diabetes-treated-with-insulin-100616693","NCT07308925","Real-time Continuous Glucose Monitoring Compared With Intermittent Continuous Glucose Monitoring in People With Type 2 Diabetes Treated With Insulin.","Effectiveness of Using Real-time Continuous Glucose Monitoring Compared With Intermittent Continuous Glucose Monitoring in People With Type 2 Diabetes Treated With Insulin.","Inclusion Criteria:\n\n* Minimum age of 35 years.\n* HbA1c \\>7.0%\n* Treatment with one or more insulin injections.\n* Stable medication regimen for the 3 months prior to study entry.\n* Insulin treatment for ≥3 months with a stable dose prior to entry, with fasting blood glucose between 70 and 130 mg\u002FdL.\n* Availability of an NFC-enabled smartphone.\n\nExclusion Criteria:\n\n* Pregnancy or planning to become pregnant during the study period.\n* History of bariatric surgery within the year prior to study entry or plans to undergo bariatric surgery during the study.\n* Having a condition that would likely require an MRI during the study period.\n* Use of medications containing high doses of ascorbic acid (\\>2000 mg\u002Fday), as it may falsely increase sensor readings.\n* Concomitant illness or condition that may compromise patient safety, including, but not limited to, serious mental illness, a diagnosed or suspected eating disorder, or any long-term medical\u002Funmanageable disorder.\n* GFR less than 30 ml\u002Fmin.\n* Psychiatric condition that interferes with study-related tasks.\n* Known (or suspected) significant allergy to medical-grade adhesives.","35 Years",{"count":78,"type":19},108,[22],"The objective is to compare the efficacy of TR-CGM versus isCGM in patients diagnosed with T2D who are treated with insulin and use CGM, as defined by time in range between 70 and 180 mg\u002FdL.\n\nAn open-label clinical trial will be conducted. Patients with T2D who use intermittent glucose monitoring and insulin with poor metabolic control will be included. They will be randomized to continue with isCGM or RT-CGM.\n\nThe primary outcome: %TIR 70-180 mg\u002FdL.",[25],[25,30,28],"2025-12-27",{"date":85,"type":36},"2025-12-30",{"date":87,"type":19},"2026-01-31",{"date":89,"type":19},"2028-12-30",{"name":42,"class":43},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":20,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":44},"100572065","comparison-of-smartguard-vs-temp-target-in-patients-with-type-1-diabetes-users-of-advanced-hybrid-closed-loop-system-ahcl-in-anaerobic-physical-activity-100572065","NCT06728423","Comparison of SmartGuard vs Temp Target in Patients With Type 1 Diabetes Users of Advanced Hybrid Closed Loop System (AHCL) in Anaerobic Physical Activity.","SmartGuard vs Temp Target in Patients With Type 1 Diabetes Users AHCL in Anaerobic Exercise","Inclusion Criteria:\n\n* Diagnosis of type 1 diabetes ≥ 1 year ago\n* AHCL users (Minimed 780G) with integrated continuous glucose monitoring\n* Use of the device for at least the last 3 months\n* Physically active (PA≥1): At least one weekly physical exercise session in the last 6 months.\n\nExclusion Criteria:\n\n* Pregnancy\n* Physical or mental inability to exercise\n* Contraindication to performing Valsalva maneuvers\n* History of osteoarticular disease that prevents exercise\n* History of tendinopathies that cause pain or limitation\n* History of coronary artery disease\n* Diabetic ketoacidosis or severe hypoglycemia in the last month\n* Evidence of autonomic failure (Unnoticed hypoglycemia given by Clarke 3 or more points Appendix 1) I am concerned because now that I am on a pump, this indication is common as support for the insulin pump.\n* Use of beta-blockers or glucocorticoids\n* Peripheral arterial disease\n* Severe proliferative diabetic retinopathy or non-proliferative diabetic retinopathy\n* Severe peripheral neuropathy\n* Stage 5 chronic kidney disease on renal replacement therapy",{"count":99,"type":19},14,[22],"Patients meeting the inclusion criteria will be identified. An informed consent form will be completed. Clinical data and baseline CGM will be collected at this appointment. During the session, an attempt will be made to establish a physical activity classification (PA0: inactive, PA1: 1-2 times per week, and PA2: more than twice per week) to determine if the patient is physically active, which is defined as at least 60 minutes of physical activity per week during the past 6 months. In addition, the patient will be asked whether or not they perform strength exercises and how regularly they do so. At the end of the first visit, they will be randomized by an electronically generated numerical sequence using the Randomizer for Clinical Trial Lite application. The patient will be scheduled to attend a supervised exercise session at the Pontificia Universidad Javeriana Sports Training Center.\n\nParticipants will have a blood glucose test prior to beginning physical activity. The target for starting exercise is 126-180 mg\u002Fdl. If the patient has a value less than 90 mg\u002Fdl, 20 grams of carbohydrates will be given; if the value is between 90-126 mg\u002Fdl, 10 grams will be given (above the investigators said that for anaerobics it could be from 90 mg\u002Fdl). If the value is higher than 200 mg\u002Fdl, the correction with rapid insulin is calculated according to your usual management. A new glucose test is performed 15 minutes later to confirm that the patient is within the target range. If the patient is within the target range, exercise is performed. If the reading remains above 200, the exercise session is canceled.\n\nAll participants are in SmartGuard mode on the Minimed 780G system. In the control group, the time target is activated 60 minutes before the activity and turned off 15 minutes after the end of the exercise. Participants randomized to SmartGuard will have no changes in device programming. Glucose measurements will be taken at the beginning and end of the exercise session. In addition, a Hooper Index will be calculated to standardize the patient's rest and recovery prior to the session. The strength training session will begin with a brief 15-minute warm-up emphasizing joint flexibility. The workout will consist of 3 sets of 10 repetitions of the following exercises: leg press, chest press, seated row. The estimated weight at which the exercises will be performed will be 60-80% of the 1-RM calculated for each patient. There will be a 90 second timed rest between each set of exercises. The total duration of the training will be 45 minutes. The strength training session begins with a short 15-minute warm-up focusing on joint flexibility. The workout consists of 3 sets of 10 repetitions of the following exercises: leg press, chest press, seated row. The estimated weight at which the exercises are performed is 60-80% of the 1-RM calculated for each patient. A timed rest of 90 seconds will be provided between each set of exercises. The total duration of the training will be 45 minutes. The parameter used to monitor intensity will correspond to the Borg scale measurement and heart rate monitoring. For each participant, the anthropometric variables will be entered into the application in order to perform the exact calculation of the target maximum heart rate (HR) percentage. The activity begins with a 5-minute warm-up at low intensity (55-65% of maximum HR, Borg 9-11), then 35 minutes at moderate intensity (70-80% of maximum HR, Borg 12-13), and ends with a 5-minute cool-down (maximum HR less than 55%). Alarms are set on the device to maintain the desired intensity. Glucose testing is performed at the beginning and end of the activity.\n\nA 14-day washout period will be carried out, after which the group of patients initially assigned to temporary target activation will perform the same exercise in SmartGuard mode; likewise, the group initially assigned to SmartGuard will do so under temporary target mode. For this second session, the same procedure and recommendations already mentioned will be carried out.\n\nCGM data will be collected through integrated continuous glucose monitoring, which downloads the information to the Carelink portal and is accessed online.",[103,104],"Type 1 Diabetes (T1D)","Exercise","2025-09-20",{"date":107,"type":36},"2025-09-25",{"date":109,"type":19},"2025-11-01",{"date":111,"type":19},"2027-11-30",{"name":42,"class":43},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":20,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":44},"100581939","functional-results-of-infiltration-for-biceps-tendonitis-guided-by-ultrasound-vs-anatomical-repairs-variation-in-technique-100581939","NCT06856824","Functional Results of Infiltration for Biceps Tendonitis Guided by Ultrasound vs Anatomical Repairs: Variation in Technique","Inclusion Criteria:\n\n* 18 years or older\n* Patients with anterior shoulder pain\n* Point of maximum pain in long head bíceps tendon at the level of the bicipital groove\n* Positive speed test\n* Patients who gave informed consent and accepted follow-up\n\nExclusion Criteria:\n\n* Calcifying tendonitis of the biceps\n* Partial or complete rupture of the subscapularis tendon\n* Glenohumeral joint deformity\n* Rupture and\u002For dislocation of the tendon of the long head of the biceps.\n* Surgery and\u002For previous infiltrations in the biceps tendon","99 Years",{"count":121,"type":19},50,[22],"A randomized clinical trial aimed at comparing the functional outcomes of brachial biceps infiltration guided by anatomical landmarks versus ultrasound guidance. Given that ultrasound guidance has shown an efficacy of 91%, this intervention could potentially be more effective in delivering medication to the target area and achieving improved therapeutic outcomes",[125],"Bíceps Tendinitis",[127,128,129,130,131],"Bíceps","Tendinitis","injection","ultrasound","corticosteroid","RECRUITING","2025-03-12",{"date":135,"type":36},"2025-03-17",{"date":137,"type":36},"2024-06-01",{"date":139,"type":19},"2025-12-31",{"name":42,"class":43},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":20,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":44},"100581961","supracondylar-radial-nerve-block-guided-by-ultrasound-versus-hematoma-block-for-analgesic-management-in-closed-reduction-of-distal-radius-fractures-100581961","NCT06857110","\"Supracondylar Radial Nerve Block Guided by Ultrasound Versus Hematoma Block for Analgesic Management in Closed Reduction of Distal Radius Fractures\"","\"Supracondylar Radial Nerve Block Guided by Ultrasound Versus Hematoma Block for Analgesic Management in Closed Reduction of Distal Radius Fractures: a Randomized Controlled Clinical Trial\"","Inclusion Criteria:\n\n* Patients over 18 years old with skeletal maturity evidenced in the initial radiographs.\n* Patients with a radiological diagnosis of distal radius fracture\n* Patients whose clinical condition is considered acute (duration of symptoms less than one week).\n* Patients who have an indication for closed reduction as a definitive or initial management of their distal radius fracture\n* Patients treated at San Ignacio University Hospital in Bogotá, Colombia\n\nExclusion Criteria:\n\n* • Patients with bilateral distal radius fractures\n\n  * Patients with open distal radius fractures.\n  * Patients with another fracture in the same limb\n  * Patients in a state of intoxication or under the influence of psychoactive substances.\n  * Patients with hemodynamic instability that prevents prioritizing closed reduction as management.\n  * Patients with a known allergy to local anesthetics\n  * Patients on full-dose anticoagulant therapy.\n  * Patients who refuse to participate in the study\n  * Patients with cognitive, visual, or auditory impairments that prevent the proper completion of questionnaires",{"count":121,"type":19},[22],"Non-surgical treatment with closed reduction and immobilization using a splint or cast is the preferred approach for stable distal radius fractures, particularly in elderly patients. It is also the initial intervention for displaced fractures with a surgical indication before the procedure, aiming to reduce edema, manage pain, and prevent associated complications. However, the maneuvers required for bone reduction can cause significant pain, and there is still insufficient evidence to favor one anesthetic method over another. In recent years, there has been a trend toward utilizing local methods, such as hematoma block or ultrasound-guided supracondylar block of the radial nerve, due to their lower incidence of complications. Nonetheless, there are currently no studies comparing the efficacy of these two analgesic approaches.\n\nThis study aims to compare the analgesic effect of ultrasound-guided supracondylar block with that obtained through hematoma block in patients with distal radius fracture during closed reduction, using the Numeric Rating Scale. Additionally, it aims to compare the quality of the reduction through radiographic measures and assess the frequency of adverse events after the two interventions.",[152],"Distal Radius Fracture",[154,155,156,157,158,159],"Wrist fractures","closed fracture reduction","analgesia","Anesthesia, local","nerve block","pain measurement",{"date":135,"type":36},{"date":137,"type":36},{"date":163,"type":19},"2025-06-30",{"name":42,"class":43},""]